Global Study to Investigate Safety and Tolerability of Donanemab in Early Symptomatic Alzheimer's Disease

TRAILBLAZER-ALZ 5 is a clinical trial that is gathering more data on a drug called LY3002813. Previous studies showed that LY3002813 was able to slow the rate of decline in people’s cognition and function over a year. The study involves a once-monthly infusion at our clinic in Malvern. 

We are looking for individuals aged 60-85 years in the early stages of Alzheimer's disease to participate. The trial involves a once-monthly infusion at our clinic in Malvern. There is a 50% chance of receiving placebo.